Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Mehr anzeigen
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd...
– Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of...
– Bolsters clinical pipeline and adds near-term value creation opportunities – – Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded therapeutic...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference...
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.67 | -8.07228915663 | 8.3 | 8.44 | 7.52 | 594425 | 7.81865238 | CS |
| 4 | -0.98 | -11.3821138211 | 8.61 | 8.97 | 7.52 | 619507 | 8.4147631 | CS |
| 12 | -2.5 | -24.6791707799 | 10.13 | 11 | 7.52 | 951905 | 9.12386545 | CS |
| 26 | -3.42 | -30.9502262443 | 11.05 | 13.09 | 7.52 | 969417 | 9.65889242 | CS |
| 52 | -4.62 | -37.7142857143 | 12.25 | 13.09 | 7.52 | 1144926 | 9.64978935 | CS |
| 156 | -41.37 | -84.4285714286 | 49 | 58 | 7.52 | 1170292 | 21.89781265 | CS |
| 260 | -8.52 | -52.7554179567 | 16.15 | 141.01 | 7.52 | 1124162 | 29.3704666 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
